company background image
MAB

Mabion WSE:MAB Stock Report

Last Price

zł27.60

Market Cap

zł446.1m

7D

1.7%

1Y

-54.8%

Updated

26 May, 2022

Data

Company Financials +
MAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance3/6
Financial Health3/6
Dividends0/6

MAB Stock Overview

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.

Mabion Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Mabion
Historical stock prices
Current Share Pricezł27.60
52 Week Highzł110.00
52 Week Lowzł22.60
Beta0.75
1 Month Change-1.43%
3 Month Change-5.80%
1 Year Change-54.75%
3 Year Change-63.25%
5 Year Change-70.95%
Change since IPO104.75%

Recent News & Updates

Dec 22
Is Mabion (WSE:MAB) Using Too Much Debt?

Is Mabion (WSE:MAB) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Sep 11
Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mabion S.A. ( WSE:MAB...

Shareholder Returns

MABPL BiotechsPL Market
7D1.7%-1.7%6.3%
1Y-54.8%-39.0%-42.2%

Return vs Industry: MAB underperformed the Polish Biotechs industry which returned -39% over the past year.

Return vs Market: MAB underperformed the Polish Market which returned -42.2% over the past year.

Price Volatility

Is MAB's price volatile compared to industry and market?
MAB volatility
MAB Average Weekly Movement14.2%
Biotechs Industry Average Movement7.1%
Market Average Movement6.8%
10% most volatile stocks in PL Market13.4%
10% least volatile stocks in PL Market4.5%

Stable Share Price: MAB is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: MAB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
2007213Krzysztof Kaczmarczykhttps://www.mabion.eu

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of malignant, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab to treat several diseases resulting in vision impairment.

Mabion Fundamentals Summary

How do Mabion's earnings and revenue compare to its market cap?
MAB fundamental statistics
Market Capzł446.07m
Earnings (TTM)zł1.90m
Revenue (TTM)zł56.87m

234.4x

P/E Ratio

7.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAB income statement (TTM)
Revenuezł56.87m
Cost of Revenuezł0
Gross Profitzł56.87m
Other Expenseszł54.97m
Earningszł1.90m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)0.12
Gross Margin100.00%
Net Profit Margin3.35%
Debt/Equity Ratio120.9%

How did MAB perform over the long term?

See historical performance and comparison

Valuation

Is Mabion undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


234.41x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: MAB (PLN27.6) is trading above our estimate of fair value (PLN11.67)

Significantly Below Fair Value: MAB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish Biotechs industry average (35x).

PE vs Market: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish market (10.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MAB is overvalued based on its Price-To-Book Ratio (27.5x) compared to the PL Biotechs industry average (3.8x).


Future Growth

How is Mabion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MAB's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if MAB's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MAB's revenue (15.3% per year) is forecast to grow faster than the Polish market (5.5% per year).

High Growth Revenue: MAB's revenue (15.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MAB's Return on Equity is forecast to be high in 3 years time (26.9%)


Past Performance

How has Mabion performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MAB has high quality earnings.

Growing Profit Margin: MAB became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 7.8% per year.

Accelerating Growth: MAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: MAB's Return on Equity (11.7%) is considered low.


Financial Health

How is Mabion's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MAB's short term assets (PLN112.7M) do not cover its short term liabilities (PLN118.5M).

Long Term Liabilities: MAB's short term assets (PLN112.7M) exceed its long term liabilities (PLN57.4M).


Debt to Equity History and Analysis

Debt Level: MAB has more cash than its total debt.

Reducing Debt: MAB's debt to equity ratio has reduced from 352% to 120.9% over the past 5 years.

Debt Coverage: MAB's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if MAB's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Mabion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.85%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

zł104k

CEO Compensation


CEO

Krzysztof Kaczmarczyk

1

Tenure

zł104,000

Compensation

Mr. Krzysztof Kaczmarczyk serves as Non-Executive Independent Director of Huuuge, Inc. He had been a Supervisory Board Member at CI Games S.A. until 2022. He served as an Independent Chairman of the Superv...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mabion S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Mabion S.A.
  • Ticker: MAB
  • Exchange: WSE
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł446.066m
  • Shares outstanding: 16.16m
  • Website: https://www.mabion.eu

Number of Employees


Location

  • Mabion S.A.
  • gen. Mariana Langiewicza 60 Street
  • Konstantynów Lódzki
  • 95-050
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/26 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.